The hippocampus is a limbic cortical structure that plays an important role in learning and memory, and is a primary site of temporal lobe epilepsy and Alzheimer's disease. Glutamate is the primary neurotransmitter at excitatory synapses in the hippocampus, where it acts on both ionotropic and metabotropic glutamate receptors (mGluRs). Particular attention has been focused on the NMDA subtype of glutamate receptor because of its unique role in certain forms of learning, memory, and pathological conditions including epileptic responses and excitotoxicity. Interestingly, recent studies reveal that activation of one mGluR subtype, mGluR5, can dramatically potentiate currents through NMDA receptor channels in hippocampal neurons. Furthermore, low concentrations of NMDA potentiate responses to mGluR5 activation. This positive feedback regulation between mGluR5 and NMDA receptors could play a critical role in signal amplification and may be important for NMDA receptor function. Consistent with this, several previous studies suggest that mGluR5 plays an important role in several receptor-dependent forms of synaptic plasticity and could contribute to pathological responses to NMDA receptor activation. Previous studies reveal that mGluR5 is desensitized by activation of protein kinase C (PKC) which directly phosphorylates the receptor. We recently found that mild activation of NMDA receptors-with low concentrations of NMDA-potentiates mGluR5-mediated responses by reversing this agonist-induced desensitization. Interestingly, stronger activation of NMDA receptors reduced mGluR5-mediated responses and increased mGluR5 phosphorylation. This is especially interesting in light of recent studies that suggest that low frequency stimulation of glutamatergic afferents to hippocampal area CA1 induces preferential activation of the protein phosphatase calcineuron whereas high frequency stimulation leads to activation of PKC and a net increase in protein phosphorylation. Based on this and a number of other previous studies, we postulated that the differential effects of different concentrations of NMDA on mGluR5 are mediated by net increases and decreases in mGluR5 phosphorylation. Furthermore, we postulate that low frequency stimulation of glutamatergic afferents induces preferential dephosphorylation of mGluR5 and potentiates mGluR5-mediated responses whereas high frequency stimulation induces a net increase in mGluR5 phosphorylation and inhibition of mGluR5-mediated responses. A combination of molecular, biochemical and electrophysiological techniques will be used to directly test these hypotheses.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH062646-06
Application #
6846078
Study Section
Special Emphasis Panel (ZRG1-MDCN-5 (01))
Program Officer
Desmond, Nancy L
Project Start
2001-02-15
Project End
2006-01-31
Budget Start
2005-02-01
Budget End
2006-01-31
Support Year
6
Fiscal Year
2005
Total Cost
$302,000
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Pharmacology
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Moran, Sean P; Cho, Hyekyung P; Maksymetz, James et al. (2018) PF-06827443 Displays Robust Allosteric Agonist and Positive Allosteric Modulator Activity in High Receptor Reserve and Native Systems. ACS Chem Neurosci 9:2218-2224
Moran, Sean P; Dickerson, Jonathan W; Cho, Hyekyung P et al. (2018) M1-positive allosteric modulators lacking agonist activity provide the optimal profile for enhancing cognition. Neuropsychopharmacology 43:1763-1771
Yohn, Samantha E; Conn, P Jeffrey (2018) Positive allosteric modulation of M1 and M4 muscarinic receptors as potential therapeutic treatments for schizophrenia. Neuropharmacology 136:438-448
Stansley, Branden J; Conn, P Jeffrey (2018) The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia. Curr Opin Pharmacol 38:31-36
Joffe, Max E; Centanni, Samuel W; Jaramillo, Anel A et al. (2018) Metabotropic Glutamate Receptors in Alcohol Use Disorder: Physiology, Plasticity, and Promising Pharmacotherapies. ACS Chem Neurosci 9:2188-2204
Foster, Daniel J; Conn, P Jeffrey (2017) Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders. Neuron 94:431-446
Sengmany, Kathy; Singh, Junaid; Stewart, Gregory D et al. (2017) Biased allosteric agonism and modulation of metabotropic glutamate receptor 5: Implications for optimizing preclinical neuroscience drug discovery. Neuropharmacology 115:60-72
Ghoshal, Ayan; Moran, Sean P; Dickerson, Jonathan W et al. (2017) Role of mGlu5 Receptors and Inhibitory Neurotransmission in M1 Dependent Muscarinic LTD in the Prefrontal Cortex: Implications in Schizophrenia. ACS Chem Neurosci 8:2254-2265
Joffe, Max E; Santiago, Chiaki I; Engers, Julie L et al. (2017) Metabotropic glutamate receptor subtype 3 gates acute stress-induced dysregulation of amygdalo-cortical function. Mol Psychiatry :
Felts, Andrew S; Rodriguez, Alice L; Morrison, Ryan D et al. (2017) Discovery of imidazo[1,2-a]-, [1,2,4]triazolo[4,3-a]-, and [1,2,4]triazolo[1,5-a]pyridine-8-carboxamide negative allosteric modulators of metabotropic glutamate receptor subtype 5. Bioorg Med Chem Lett 27:4858-4866

Showing the most recent 10 out of 93 publications